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Background: Mutations in the SQSTM1/p62 gene have been reported in Paget’s disease of bone (PDB), but they
are not sufficient to induce the pagetic osteoclast (OC) phenotype. We hypothesized that specific RNA isoforms of
OC-related genes may contribute to the overactivity of pagetic OCs, along with other genetic predisposing factors.
Methods: Alternative splicing (AS) events were studied using a PCR-based screening strategy in OC cultures from
29 patients with PDB and 26 healthy donors (HD), all genotyped for the p62P392L mutation. Primer pairs targeting
5223 characterized AS events were used to analyze relative isoform ratios on pooled cDNA from samples of the four
groups (PDB, PDBP392L, HD, HDP392L). Of the 1056 active AS events detected in the screening analysis, 192 were
re-analyzed on non-amplified cDNA from each subject of the whole cohort.
Results: This analysis led to the identification of six AS events significantly associated with PDB, but none with
p62P392L. The corresponding genes included LGALS8, RHOT1, CASC4, USP4, TBC1D25, and PIDD. In addition, RHOT1
and LGALS8 genes were upregulated in pagetic OCs, as were CASC4 and RHOT1 genes in the presence of p62P392L.
Finally, we showed that the proteins encoded by LGALS8, RHOT1, USP4, TBC1D25, and PIDD were expressed in
human OCs.
Conclusion: This study allowed the identification of hitherto unknown players in OC biology, and our findings of a
differential AS in pagetic OCs may generate new concepts in the pathogenesis of PDB.
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Osteoclasts (OCs) are multinucleated cells, whose pheno-
type includes the expression of the calcitonin receptor
(CTR) and of the Receptor Activator of NF-κB (RANK),
and the singular ability to resorb bone [1,2]. OC formation,
activity and survival are regulated by two major signaling
pathways, which are activated by M-CSF and RANKL
(Receptor Activator of NK-κB Ligand).
Paget’s disease of bone (PDB) is characterized by focal
and disorganized increases in bone turnover, and OCs
have been identified as the cells primarily affected in
PDB [3]. Pagetic OCs are both larger and more numerous
than those in healthy individuals. They are overactive
and hypersensitive to osteoclastogenic factors [4], and* Correspondence: sophie.roux@usherbrooke.ca
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unless otherwise stated.are resistant to apoptosis [5]. The SQSTM1 gene encodes
the ubiquitin-binding protein sequestosome 1, also known
as p62. Mutations in the SQSTM1 gene have been identi-
fied in a high proportion of PDB patients [6], the p62P392L
substitution being the most frequent [7]. In PDB, p62P392L
contributes at least in part to the induction of an activated
stage in OCs by stimulating signaling pathways that can lead
to NF-κB activation [5,8]. In vivo, knock-in mice expressing
p62P394L (the murine equivalent of human p62P392L) de-
velop focal osteolytic lesions, some of which resemble
PDB lesions [9], although in another study, co-expression
of the measles virus nucleocapsid gene in the OC lineage
was required [4]. Therefore SQSTM1 mutations may not
be sufficient to induce the pagetic OC phenotype, and en-
vironmental factors such as viral infection may contribute
[4]. Two recently published genome-wide association stud-
ies (GWAS) in PDB patients free of SQSTM1 mutations
identified seven significant genetic variants for susceptibilitytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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NUP205, SLC13A4), 8q22 (TM7SF4), 10p13 (OPTN),
14q32 (RIN3), 15q24 (PML, GOLGA6A), and 18q21
(TNFRSF11A) loci [10,11]. This implies that genes
other than SQSTM1 may also contribute to the patho-
genesis of PDB, although so far only disease-causing
mutations in SQSTM1 have been identified. Besides
gene expression modulation or mutations, other mech-
anisms regulate phenotypic variations in cells through
post-transcriptional processes such as alternative spli-
cing (AS) that leads to a vast array of transcripts with
diverse functions. We hypothesized that specific RNA
isoforms of OC-related genes may contribute to the
pagetic OC phenotype. Our objective was therefore to
look for PDB-specific AS events in these cells, and to
investigate the impact of the p62P392L mutation.
Methods
Materials
Opti Eagle’s minimum essential media (Opti-MEM),
penicillin, streptomycin, fungizone, glutamine, and fetal calf
serum (FCS) were purchased from Wisent (Montreal, QC).
Ficoll–Paque was purchased from Amersham Biosciences
(Montreal, QC). Human recombinant (hr) M-CSF, and
hrGM-CSF were purchased from R&D (R&D Systems,
Minneapolis, MN); soluble hrRANKL was produced in our
laboratory. Rabbit polyclonal antibodies against human
PIDD (#ab78389), Galectin 8 (#ab41649), and RHOT1
(#ab83779) were purchased from Abcam (Cambridge, MA);
rabbit polyclonal antibodies against human TBC1D25
(OATL1) (#HPA029197), and USP4 (#U0635) were
purchased from Sigma-Aldrich (St. Louis, MO), and
fluorescent Alexa antibodies, Di Aminido Phenyl lndol
(DAPI), and siRNA from Invitrogen (Burlington, ON).
Clinical investigation and phenotype classification
Blood samples from each of the healthy donors (HD) and
PDB patients were provided by authors JPB and LM. This
research has been approved by the Ethics Committees of
the CHU de Québec. All participants signed an informed-
consent document before entering the study. Phenotypic
expression of PDB had been previously established (JPB)
in all participants based on: total serum alkaline phosphat-
ase, total body bone scan, skull and enlarged view pelvis
X-rays, and if needed, additional X-rays to confirm PDB,
as described [12]. Exons 7 and 8 of the gene encoding
SQSTM1/p62 had been previously sequenced in every
donor and patient [13]. The p62P392L mutation was the
only SQSTM1 mutation identified in individuals par-
ticipating in this study. Fifty-five participants, 29 PDB
(13 females, 16 males) and 26 HD (16 females, 10 males),
were divided into four groups: healthy donors exempt from
any known mutation in the SQSTM1/p62 gene (HDwt);
healthy donors carrying the p62P392L mutation (HDP392L),these donors came from families with PDB history (carrying
the p62P392L mutation), but had no phenotypic expression
of PDB at the time of study; PBD patients exempt from any
known mutation in the SQSTM1/p62 gene (PDBwt); PDB
patients carrying the p62P392L mutation (PDBP392L).
Cell cultures
Peripheral blood mononuclear cells (PBMCs) were isolated
from heparinized blood by density-gradient centrifugation,
and suspended in Opti-MEM with the antibiotics, glutam-
ine, and 2% FCS. After incubating overnight, the cells were
gently washed to remove any non-adherent cells. The se-
lected PBMCs were cultured in Opti-MEM supplemented
with GM-CSF (100 pg/ml) for the first 3 days, and then for
a further 3 weeks in the same medium supplemented with
M-CSF (25 ng/ml) and RANKL (75 ng/ml). The medium
was changed every 2–3 days. Alternatively, blood was har-
vested from human umbilical cord at delivery after obtain-
ing informed consent from parturient women, as approved
by our institution’s review board (University of Sherbrooke).
Cord blood monocytes (CBMs) were isolated and processed
as described above. These culture conditions generate mul-
tinucleated cells (MNC) that express OC markers and have
the ability to resorb bone [5,14]. Human embryonic kidney-
293 T (293 T) cells were cultured in DMEM containing
10% FCS, glutamine and antibiotics.
Alternative splicing
Total cellular RNA was extracted from fully matured OCs,
reverse transcribed, and analyzed by high-throughput PCR
amplification at the Université de Sherbrooke RNomics
Platform as previously described [15,16]. Five (5) ng of total
RNA was used for each PCR experiment. For the detection
screening we used RNA pre-amplified using a linear isother-
mal RNA amplification (Transplex Whole Transcriptome
Amplification Kit, Sigma, Markham, ON) following the
manufacturer’s protocol. AS events were characterized by
end-point PCR. Primers were designed to flank the AS
events, such that following amplification and analysis by
microcapillary electrophoresis on Caliper LC-90 instru-
ments (Caliper Life Sciences, Hopkinton, MA), the relative
ratio of the isoforms can be deduced [15]. AS events which
were amenable to characterization by high-thoughput PCR,
that is, whose isoform sizes differ by between 10 and 450
nucleotides at a particular event, were selected from the
RefSeq database [16]. Automated querying of this highly
curated database has identified a genome-wide selection of
5223 AS events which fit the selection criteria from the full
set of over 20 K human gene entries [16].
Detection screen
In the first step of the screen, termed the “detection
screen”, primer pairs targeting the 5223 AS events
were used to perform PCR and microcapillary analysis
Table 1 siRNA sequences
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four groups, each sample being a pooled RNA from
five patients (60 ng of total RNA per individual needed
prior to pre-amplification). The purpose of this screen
was to detect AS events in the sample pools for which
both isoforms were detectable to a minimum of 10% of
the total signal in at least one of the samples. Such AS
events are designated as “active”. If only one form of
the event is detected in all samples, or if no amplifica-
tion of the expected products occurs, these AS events
were not considered for subsequent validation.
Validation screen
Next, during what we term the “validation screen”, we
analyzed the active AS events in PCR experiments on
non-amplified RNA in our cohort of 55 individuals,
using the same primers, however in this screen, the rela-
tive amounts of long and short isoforms issued from the
microcapillary analysis of the amplification reaction was
considered. The splicing profile from each PCR reaction
was expressed as a percent splicing index (PSI or Ψ)
which is the ratio of the long isoform concentration to the
total (long + short) isoform concentrations, expressed as a
percentage. The Ψ values of the active AS events were
compared in the four groups. The use of multiple samples
reduces the impact of individual aberrant AS, artefacts re-
lated to the pre-amplification procedure, and to confirm
the PDB-specific events.
Gene expression study
For the quantitative real-time RT-PCR analysis, total RNA
was extracted from fully matured OCs using the RNeasy
plus kit (Qiagen, Mississauga, Canada), including a DNase
digestion step. At least 50 μg of RNA was harvested from
each cell sample. After being assayed and checked for
quality, 1 μg of total RNA was reverse transcribed using
the high-efficiency QuantiTect Primer Assay kit (Qiagen),
and sent for quantitative PCR amplification (RNomics
Platform, University of Sherbrooke). Human primers
of candidate genes were generated and validated, and
the real-time PCR reaction was conducted with 200 nM
of primers, 10 ng of cDNA and 5 μl of Power SYBR-green
Master Mix in a total volume of 10 μl. Amplification and
detection of the candidate genes and of three reference
genes (Splicing factor 3a, subunit 1 (SF3A1), Proteasome
26S subunit ATPase 4 (PSMC4), Pumilio homolog 1
(PUM1)) were conducted with a Realplex 2 Master Cycler
(Eppendorf, Mississauga, Canada).
We investigated the relative expression of genes for
which AS events were significantly associated with PDB
in OC cultures. All the primers were designed based on
sequences reported in the Aceview database [17]. Three
primer pairs were designed for each gene, in order to
choose the best primer pair after validation. All primerspairs were validated by qPCR amplification of a total
XPressRef Universal human mRNA (Cedarlane, Burlington,
ON). Amplification products were submitted to capillary
electrophoresis in order to validate the size of the expected
product. In addition, a melting curve was generated and
only those primers giving one product were selected. If all
the three primer pairs gave such results, the pair giving the
lowest Ct was selected. Finally, the primer pair efficiency
was obtained from a standard curve experiment where
a series of dilution of the same sample was correlated
to the Ct values.
All samples were run in triplicate for the target and
reference genes. Relative expression levels were nor-
malized with respect to a set of reference primer pairs
(i.e. the geometric mean of the three reference genes).
Relative expression quantification analysis relied on the
qBase method [18]. This method constitutes an improve-
ment over the classical delta-delta-Ct method, which was
extended to take into account multiple stably expressed
reference genes for improved normalization.
RNA inactivation
Seventy-two to 96 hours before lysing cells, 293 T cells
were transfected either with a specific siRNA (50 nM), or
with a negative control siRNA (scrambled siRNA) in a solu-
tion containing Lipofectamine 2000 Transfection Reagent
in serum-free Opti-MEM. One specific siRNA was used to
inhibit each gene (PIDD, TBC1D25, RHOT1, LGALS8), two
siRNAs against USP4 were used in combination (Table 1).
The cells were incubated at 37°C for 2 hours. The subse-
quent downregulation of all targeted proteins was assessed
by western-blotting.
Western-blotting
Cells were cultured as described above. Proteins were
extracted and lysates were quantified by modified
Bradford assay (Bio Rad, Mississauga, ON) and run
through SDS-PAGE. Western-blots were performed
by incubating a primary antibody against Galectin 8,
RHOT1, USP4, TBC1D25, PIDD, or β-actin where ap-
propriate overnight at 4°C. HRP-conjugated secondary
antibodies were used to achieve detection with a
chemiluminescent system.
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At the end of the OC cultures, cells were washed quickly
with cold PBS, fixed with 1% para-formaldehyde, and
then permeabilized in PBS-Triton X-100 (0.2%). Specific
antibodies directed against USP4, TBC1D25, and PIDD
were incubated in Antibody diluent (DAKO) overnight at
4°C. Alexa-488 (green) anti-rabbit antibodies were incu-
bated for 2 h at room temperature, along with Alexa Fluor
633 phalloidin. DAPI counter-staining was performed, so
that OCs containing more than three nuclei could be visu-
alized. Sequences of pictures were taken with appropriate
filters to show all three colors, and superimposed with
Simple PCI software.
Statistical analysis
We studied four groups (PDBwt, PDBP392L, HDwt, HDP392L)
in six intergroup analyses (all PDB vs all HD; all PDB
patients vs HDwt; PDBwt vs HDwt, PDBwt vs HDP392L, PDBwt
vs PDBP392L; and HDwt vs HDP392L). Student’s t-tests were
applied to the Ψ values for each AS event in each group
and Ψ value changes with values of p < 0.05 were consid-
ered to be significant, with a correction for multiple testing
using the false discovery rate or q-value [19]. For genes in
which we confirmed the presence of specific AS events of
PDB OCs, we looked for association with the P392L muta-
tion using Fisher exact tests. For gene expression analysis,
the fold change was calculated as the ratio of the mean rela-
tive expression for each group, and results were expressed
as the base 2 logarithm of the fold change. Statistical signifi-
cance was defined as p < 0.05 using a Student’s t-test.
Results
Alternative splicing in Paget’s disease of bone
To perform our study of AS in PDB, we used a validated
model for the in-vitro study of human OCs involving
peripheral blood mononuclear cells (PBMCs) [5]. We
studied OC cultures from a cohort of patients (PDB) and
healthy donors (HD), all genotyped for the p62P392L muta-
tion, and representing four distinct groups: HDwt (n = 16,
mean age 61 years; 39–84), HDP392L (n = 10, mean age
51.3 years; 33–70; of which three were under 52 years old),
PDBwt (n = 17, mean age 70.7 years; 45–86), PDBP392L
(n = 12, mean age 75 years; 59–85). In the first step of the
AS screen, termed the “detection screen”, primer pairs tar-
geting 5223 characterized AS events were used to amplify
and evaluate the relative isoform ratios on pooled cDNA
from our four groups (5 patients in each group). 1056 of
the targeted AS events showed evidence of regulation, and
were thus classified as “active”. Three genes of the 5223
tested AS events (VDR, OPTN, and PML) had been previ-
ously associated with PDB [6,11], of which OPTN and PML
displayed active AS events.
From this active list (n = 1056), 192 AS events (in 164
genes) were selected based on genes that have a confirmedor potential function in the OC phenotype, function or
signaling pathways, or those whose involvement in PDB
has been suggested [5,10,20] (Additional file 1: Table S1).
The 192 active AS events were then tested in a “validation
screen”. Five individuals from each group were analyzed
separately using the computed Ψ values (see Methods) to
compare profiles between groups. This screen yielded 21 AS
events that were either significantly associated with PDB or
with the p62P392L mutation (t-test, p < 0.05, Additional file 2:
Table S2). We then confirmed this association by analyzing
these 21 active AS events by PCR on cDNA from the
remaining non-tested individuals (12 PDBwt, 7 PBDP392L, 11
HDwt, 5 HDP392L), and Ψ values were compared (Table 2).
This led to the identification of six AS events that were
significantly associated with PDB, corresponding to: LGALS8
(galectin-8), RHOT1 (mitochondrial Rho GTPase1), CASC4
(cancer susceptibility candidate 4), USP4 (ubiquitin specific
protease 4), TBC1D25 (TBC1 domain family, member 25),
and PIDD (p53-induced death domain protein) (Table 3).
No significant association of AS profile with the p62P392L
mutation was found.
Expression of genes with PDB-related AS events in OCs
The OC gene expression profiles of the six genes LGALS8,
RHOT1, CASC4, USP4, TBC1D25, and PIDD, were ana-
lyzed in the four groups (12 PDBwt, 10 PBDP392L, 12 HDwt,
10 HDP392L), and the results in PBD patients relative to
healthy donors, in presence of the p62P392L mutation or
not, are shown in Figure 1. In the comparison between
the gene expression (mean +/− SEM) in all PDB patients
regardless of whether the p62P392L mutation was present or
not versus non-mutated healthy donors, there was a signifi-
cant up-regulation in the RHOT1 gene (1.06 ± 0.04 in PBD
vs 0.85 ± 0.03 in HDwt, p =0.002), and to a lesser extent in
the LGALS8 gene (1.07 ± 0.03 vs 0.94 ± 0.03, p =0.015) in
PDB patients. When comparing the relative gene expres-
sion between OCs from PDB patients carrying p62P392L
and PDB patients with no mutation in the SQSTM1 gene,
we observed a significant increase in the expression of the
CASC4 gene in presence of the mutation (1.34 ± 0.09 in
PDBP392L vs 1.01 ± 0.04 in PDBwt, p =0.002), and in the
expression of RHOT1 (1.17 ± 0.06 vs 0.97 ± 0.04, p =0.021).
Finally, the relative expression of two genes was signifi-
cantly upregulated in OC cultures from HD carriers of
p62P392L compared to healthy donors with no mutation
in the SQSTM1 gene, with an upregulation of CASC4
(1.39 ± 0.40 in HDP392L vs 1.05 ± 0.11 in HDwt, p = 0.015),
and RHOT1 genes (1.02 ± 0.06 in HDP392L vs 0.85 ± 0.06 in
HDwt, p = 0.026) (Figure 1).
Protein expression of PIDD, TBC1D25, RHOT1, LGALS8 and
USP4 in mature OCs
A major interest of this study is that it enabled us to
identify AS events from genes not previously known to
Table 2 Validation of the selected 21 alternative splicing events in the whole cohort
Gene Forward Primer Reverse Primer all PDB vs HD all PDB vs HDwt PDBwt vs HDwt PDBwt vs HDP392L PDBwt vs PDBP392L HDwt vs HDP392L
(n =19 vs 16) (n =19 vs 11) (n =12 vs 11) (n =12 vs 5) (n =12 vs 7) (n =11 vs 5)
p* q p q p q p q p q p q
LGALS8 ACACTCTGGGCATTTATGGC TTTAACGACGACAGTTCGTCC 0.00001 0.0002 0.0005 0.009 0.0004 0.004 0.001 0.008 0.64 0.55 0.71 0.55
USP4 AGCTATTCAACATCCCTGCG GGTGGCTCCTGACAATTATACG 0.0002 0.0012 0.0019 0.013 0.002 0.006 0.033 0.054 0.73 0.55 0.48 0.51
CASC4 GAGGTGGTGATGCAGGGATGC GATCCATTTGAAGCTCTCGTTCTTC 0.001 0.004 0.001 0.009 0.001 0.004 0.050 0.07 0.15 0.27 0.22 0.39
RHOT1 TCCACCACAAGCCTTCACTT GTGCACATACAGCGTAACCG 0.001 0.004 0.018 0.061 0.021 0.042 0.003 0.0019 0.88 0.59 0.89 0.66
PIDD ATGTTCGAGGGCGAAGAGTT CGCCACGGTAGAAGGACAC 0.01 0.03 0.03 0.08 0.03 0.04 0.03 0.05 0.68 0.55 0.62 0.51
LGALS9 GTGATGGTGAACGGGATCCT GTTGGCAGGCCACACGCC 0.02 0.03 0.053 0.11 0.14 0.18 0.10 0.12 0.38 0.42 0.81 0.68
TBC1D25 AATGTGAGAGCTTCTTGCCG AGGATGGACTGTGTAAAGGGC 0.03 0.05 0.04 0.10 0.01 0.02 0.02 0.05 0.04 0.24 0.35 0.39
THAP1 AGGACAAGCCCGTTTCTTTC TCCAATAGCAGCATCAACCTG 0.04 0.09 0.01 0.051 0.01 0.04 0.43 0.44 0.53 0.49 0.27 0.39
ABTB1 GAGCAGCGAGACGTGGAG GCTTGTAATCGCGTAGAGCC 0.09 0.33 0.01 0.057 0.02 0.08 0.56 0.44 0.12 0.27 0.08 0.39
WARS AGCGTGACCAGTGGCCAC GCCTTTTGCACTGCTTGTCT 0.28 0.39 0.51 0.67 0.84 0.85 0.48 0.44 0.15 0.27 0.50 0.55
PIDD CTGAGCTTGGACCTGTACCC AGGCCACTCAGACCAGCG 0.23 0.39 0.42 0.65 0.47 0.59 0.73 0.47 0.03 0.24 0.27 0.39
METTL13 CATGCGTGCGTTTGTCGT ATGTCGATGTTCACTATATCCCG 0.42 0.56 0.78 0.87 0.50 0.50 0.01 0.05 0.11 0.27 0.29 0.39
L3MBTL CCAAGTGGACCATCGATGAG AGCAAATGAGTGGGTAGAGAGC 0.34 0.56 0.22 0.43 0.24 0.49 1.00 0.56 0.82 0.59 0.22 0.39
BTC ACCACCACACAATCAAAGCG TTACGACGTTTCCGAAGAGG 0.41 0.56 0.57 0.70 0.80 0.79 0.75 0.47 0.19 0.29 0.51 0.51
NLRP12 TCAGTGTGAACCAGAGCCTG CAGGTAAAGGTCGGTCAAGG 0.41 0.56 0.80 0.87 0.38 0.50 0.03 0.05 0.22 0.29 0.25 0.39
CASC4 GCTCAAACTTGGACAGTGAACC GCAGGATCCATTTGAAGCTC 0.66 0.92 0.42 0.65 0.24 0.48 0.87 0.52 0.37 0.42 0.21 0.39
ABI1 AGTTCTGGATGATGTGGGCC TGGCGGTTTCTGAGTAGGAGGA 0.85 0.94 0.46 0.65 0.37 0.50 0.52 0.44 0.48 0.49 0.20 0.39
RAB3IP TGGGATTACAACCTATCCGG CCCTGCTGAATGTATCGAATG 0.89 0.94 0.44 0.65 0.50 0.53 0.44 0.44 0.98 0.63 0.24 0.39
PRMT2 GCTCCTGGAAAGGACCGTC TTAGGCTCTGCCTCATAACTGC 0.85 0.97 0.93 0.87 0.93 0.85 0.70 0.47 n/a n/a 0.28 0.39
BCL2L12 TCCTAGCTGCCTTCCTTAG GTATGGCTTCCTTCTCTGTC 0.87 0.92 0.86 0.87 0.48 0.61 0.58 0.44 0.14 0.27 0.95 0.68
BCL2L15 TTGAGGAACAAACGGAATGC AGCTAAGCTGGAATCCTGAGC 0.98 0.98 0.91 0.87 0.87 0.82 n/a n/a n/a n/a n/a n/a
*Student’s t-test of Ψ (PSI) values for each AS event in each group (p-value) with a correction for multiple testing using the false discovery rate (q-value).
HDwt healthy donors exempt from SQSTM1/p62 mutation (n=11); HDP392L healthy donors carrying p62P392L (n=5); PBD (Paget’s disease of bone); PBDwt patients exempt from SQSTM1/p62 mutation (n=12); PDBP392L



















Table 3 Selection of six genes whose alternative splicing is associated with Paget’s disease of bone (PDB)










cassette exon, 142 nt,
coding region, in frame
- isoform 1: 317 aa, 36 kDa (short) 0.08 (0.04) 0.14 (0.04) 0.00001
- isoform 2: 359 aa, 40.5 kDa (long)
USP4 ubiquitin specific peptidase 4 cassette exon, 141 nt,
coding region, in frame
- isoform 1: 963 aa, 109 kDa (long) 0.20 (0.04) 0.27 (0.06) 0.0002
(proto-oncogene) - isoform 2: 916 aa, 104 kDa (short)
CASC4 cancer susceptibility candidate 4 cassette exon, 168 nt,
coding region, in frame
- isoform 1: 436 aa, 49 kDa (long) 0.21 (0.06) 0.29 (0.06) 0.001
- isoform 2: 380 aa, 43 kDa (short)
- isoform 3: 177 aa, 21 kDa
RHOT1 ras homolog family member T1 cassette exon, 96 nt,
coding region, in frame
- isoform 1: 618 aa, 71 kDa 0.16 (0.04) 0.23 (0.08) 0.001
- isoform 2: 659 aa, 75 kDa (short)
- isoform 3: 691 aa, 80 kDa (long)
MIRO1
- isoform 4: 580 aa, 66 kDa
PIDD p53-induced death domain
protein
3′ AS site, 51 nt, coding
region, in frame
- isoform 1 910 aa, 100 kDa (long) 0.63 (0.06) 0.58 (0.05) 0.01
- isoform 2: 893 aa, 98 kD (short)
- isoform 3: 753 aa, 83 kDa
LRDD
- isoform 4: 597 aa, 67 kDa
TBC1D25 TBC1 domain family, member 25 cassette exon, 155 nt,
5′ untranslated region
- isoform 1: 688 aa, 76 kDa (long) 0.63 (0.05) 0.68 (0.06) 0.03
OATL1 - isoform 2: 100 aa, 10 kDa (short)
*The “long” and “short” isoforms correspond to the “long” and “short” mRNA variants we investigated.
PBD (Paget’s disease of bone) (n=19); HD healthy donors (16).
**The Ψ (PSI) values for each AS event have been t-tested (p-value) (all PBD vs HD).
Figure 1 Gene expression profile of the six selected genes. We investigated the relative gene expression profile of the six genes with an AS
event significantly associated with PDB (CASC4, LGALS8, PIDD, RHOT1, TBC1D25, USP4) in OC cultures from 22 PDB patients (including 10 PDBP392L)
and 22 healthy donors (HD) (including 10 HDP392L). Total RNA extraction was performed on cultures from PBMC-derived OCs, followed by
real-time PCR experiments. Relative levels were normalized with respect to a set of three reference genes. We compared the mean, normalized,
relative expression between the four groups using Student’s t-test. Differential expression is reported as the log2 ratio. Comparisons between all
PBD and HDwt, PBDP392L and PBDwt as well as HDP392L and HDwt are presented. *p < 0.05, **p < 0.01.
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http://www.biomedcentral.com/1471-2350/15/98be associated with OC biology. We therefore studied
the expression of these genes in human OCs at the
protein level, focusing on five genes (PIDD, TBC1D25,
RHOT1, LGALS8 and USP4), as they were previously
reported for their involvement in NF-κB signaling,
apoptosis, autophagy, and ubiquitination in other systems,
which are collectively recognized as pathways essential to
OC biology [21]. As we were unable to find functioning
antibodies against CASC4, it was excluded from further
study. To evaluate the expression of the encoded proteins,
we used OCs derived from cord blood monocytes (CBMs),
and investigated the protein-level expression by im-
munofluorescence and western blot using specific anti-
bodies. Our objective was to confirm the expression of
the proteins encoded by the selected genes in human
OCs, for which the CBM-derived OCs represent a reliable
model [8,14,22].
Western blotting showed that all the proteins encoded
by the PIDD, TBC1D25, RHOT1, USP4, and LGALS8
genes were indeed expressed in human OC cultures
(Figure 2). To identify and validate some of the isoforms
of the candidate proteins observed in OCs, we also ana-
lyzed the effects of siRNA-mediated depletion of these
genes (Table 1) at the protein level. 293 T cells were
used for this as OCs cannot be transfected so efficiently.
The antibodies used were all directed against a peptide
shared by all the described isoforms for each of the pro-
teins, except for anti-TBC1D25 antibodies, which are
directed against a peptide within isoform 1 but contain-
ing only 25% of the isoform 2 sequence. PIDD isoform 4
(70 kDa) was the main isoform expressed by OCs, and
its expression was confirmed by siRNA knockdown.
Two other bands of higher MW (130 kDa and 85 kDa)
were also detected in OCs and may correspond to the
other isoforms (1/2 and 3, respectively), but were not
clearly down-regulated by siRNA. The expression of the
long isoform 1 of TBC1D25 was specifically detected
(80 kDa). Two isoforms of RHOT1 were primarily de-
tected in OCs (55 and 65 kDa), but we were not able to
differentiate between specific isoforms as the observed
bands migrated faster than predicted. Two proteins of
high MW (95 and 110 kDa) were detected in the USP4
analysis, which may correspond to the two known isoforms.
Only one Galectin 8 isoform of 42 kDa was specifically
detected (Figure 2).
The same protein profile was observed in OC cultures
from non-mutated PDB or HD, and we were not able to
quantify the expression of the short and long isoforms
(as defined in Table 3), as the long and short isoforms
of four candidate proteins (PIDD, RHOT1, USP4, and
galectin-8) showed similar migration rates. The relative
expression of TBC1D25 long isoform 1 (the short isoform
being non-detectable) was significantly lower in PDB OCs
compared to HD OCs (p =0.009) (Figure 3).In order to compensate for effects potentially attributable
to non-osteoclastic cells included in the populations used
for western blotting, we included single-cell analysis using
immunofluorescence to evaluate the expression of the
PIDD, TBC1D25, and USP4 encoded proteins in human
OCs. We found that mature multinucleated OCs expressed
PIDD, predominantly in the nucleus. The expression of
TBC1D25 and USP4 was cytoplasmic in OCs (Figure 4).
Discussion
AS plays a central role in protein diversity and post-
transcriptional gene regulation. The role of AS in the
production of oncogenes and tumor suppressors is of
major interest, as variants of these genes are often found
specifically in tumors from diverse tissues [23,24]. In
non-neoplastic diseases, the functional importance of
AS is best demonstrated by its capacity to cause diseases
such as muscular dystrophies and premature-aging dis-
orders [25]. In spite of its imposing biological relevance,
little is known about the effects of AS isoforms in bone
diseases. Splicing site SQSTM1 mutations in PDB have
been reported at least twice [26,27]. Alternative splicing
mutations have also been reported in other bone dis-
eases, such as in TCIRG1-linked autosomal recessive
osteopetrosis [28], however the present study is the first
to investigate AS in OCs in PDB. A major strength of
our approach lies in using human OCs derived from cir-
culating OC precursors from PBD patients and healthy
controls. Culture of OCs in vitro may help to identify
the genetic contribution that may cause intrinsic alter-
ations in OCs, by comparison with appropriate normal
donors. We hypothesized that specific RNA splicing of
OC-related genes may contribute to the OC phenotype
and the clinical expression of PDB. Using a screening
strategy that has been applied to cancer research in our
institution [16], we found AS events significantly associ-
ated with PDB, but not with p62P392L, in six genes:
LGALS8, RHOT1, CASC4, USP4, TBC1D25, and PIDD.
While gene selection biases may have been present in
both the detection and validation screens, as, for eco-
nomic reasons, not all known AS events were screened,
the identification of the six candidate genes from this
small subset underscores potentially significant role of AS
in the development and progression of PDB. Upregulation
of LGALS8 and RHOT1 genes was observed in pagetic
OCs, and the p62P392L mutation was associated with an
upregulation of RHOT1 and CASC4. The encoded pro-
teins were all detected in immunoblotting analyses in OC
cultures, and three of them (PIDD, TBC1D25 and USP4)
were expressed in human mature OCs. While not all
isoforms have been clearly discriminated by western
blot analysis, thus limiting our capacity to examine isoform
ratios between PBD and HD at the protein level, subtle
changes in the splice-isoform ratios might be associated
Figure 2 Western blot analysis of PIDD, TBC1D25, RHOT1, USP4 and LGALS8 encoded proteins. The expression of PIDD, TBC1D25, RHOT1, USP4
and LGALS8 was analyzed by western blot of a protein extract of OC cultures derived from CBMs, and from 293 T cells. β-actin was used as an internal
control. 293 T cells were transfected with a scrambled control siRNA (scramble), or with an siRNA specific for each gene (regions common to all isoforms
were targeted). Western blot analyses of each encoded protein were performed 72 to 96 hours post siRNA transfection in 293 T cultures, and in OC cultures,
with antibodies directed against PIDD, TBC1D25, RHOT1, USP4 and LGALS8 proteins or actin. Images are representative of three independent experiments.
Two different gels are shown for the analysis in OCs. Putative isoforms are indicated to the left of each gel image (numbering from Table 3).
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Figure 3 Western blot analysis of PIDD, TBC1D25, RHOT1, USP4 and LGALS8 encoded proteins in pagetic or control OCs. The protein
expression of the candidate genes was analyzed in OC cultures derived from PDB or HD without any p62 mutations. A- Western blot analyses of
each encoded protein were performed using antibodies directed against PIDD, TBC1D25, RHOT1, USP4 and LGALS8 proteins or actin. B- Optical
densities for bands corresponding to each protein were corrected with the optical density obtained for bands corresponding to actin, and
computed in graphical representations (n = 4 to 6 in each group, in 2 independant experiments). Analyses are reported as mean ratio ± SD
(*p≤ 0.05, ** p≤ 0.01).
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evidence of an AS modulation in PDB, our findings also
enabled us to identify AS events from genes not previ-
ously known to be associated with OC biology.
In OCs, the p62 scaffolding protein is one of the
functional links reported between RANKL and TNFR-
associated factor 6 (TRAF6)-mediated NF-κB activation
[21,30]. Protein p62 promotes the binding of CYLD to
TRAF6 [31], a de-ubiquitinating enzyme (DUB) that
negatively regulates NF-κB activity by reducing TRAF6
auto-ubiquitination [32]. The p62P392L mutation abol-
ished CYLD interaction and enhanced OC formation
and activity [33]. USP4 (Ubiquitin-specific peptidase 4)
is another DUB, of which two isoforms are produced
by AS in humans [34]. Its functional properties include
the de-ubiquitination of TAK1 [35], an important kin-
ase in the RANKL-induced signaling complex [36]. In
HEK293 cells, USP4 has also been shown to associate
with TRAF6 and to inhibit TRAF6 ubiquitination, andconsequently NF-κB activation [37]. USP4 could there-
fore play a role in the p62/TRAF6-related signaling in
pagetic OCs.
Pagetic OCs are overactive and resistant to apoptosis,
a phenotype partly related to p62P392L [5]. We found a
differential splicing in RNA of genes involved in apop-
tosis (CASC4, RHOT1, PIDD). The increased expres-
sion of CASC4 has been associated with HER-2/neu
proto-oncogene overexpression, a membrane tyrosine kin-
ase linked to cell proliferation and survival pathways [38].
RHOT1, also named MIRO-1, is a Rho GTPase involved
in mitochondrial transport. Overexpression of its constitu-
tively active mutant resulted in an increased apoptotic rate
[39]. LGALS8 encodes Galectin-8, a beta-galactoside-
binding lectin which has been implicated in cell
spreading [40,41], and in the modulation of neutrophil
functions [42]. Galectin-8 also appears as a potent
pro-apoptotic agent in T cells and inflammatory cells
[43,44], and is a strong inducer of ERK activation [41,44].
Figure 4 Immunofluorescent analysis of TBC1D25, USP4 and PIDD encoded proteins in mature human OCs. Immunofluorescence tests
were performed on mature osteoclasts derived from CBMs, using antibodies directed against each protein (encoded by TBC1D25, USP4 and PIDD),
and fluorescent secondary antibodies as well as Alexa Fluor 633-conjugated phalloidin. Nuclei were stained with DAPI. Images are representative
of three independent experiments. Scale bar represents 10 μm.
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PIDD, also named LRDD (leucine-rich repeats and death
domain containing), is an effector of p53-induced apop-
tosis. PIDD is able to induce NF-κB activation [45], but is
also able to form a caspase- 2-activating platform to cause
cell death [46]. PIDD isoform 1 is the only isoform able to
activate caspase-2, whereas isoforms −1, −2, −3 activate
NF-κB [47]. Isoform 4 is regulated by p53 and when over-
expressed independently promotes apoptosis [48]. While
isoform 4 did not show significant differences between
PDB and non-PDB samples, and isoform 2 did not pass
the detection screen selection criteria, we found a slight
decrease in isoform 1 relative to isoform 3 in PDB sam-
ples, implying a more anti-apoptotic behaviour of PIDD
in PDB than non-PDB samples. None of these genes
(PIDD, RHOT1, LGALS8) has ever been associated with
PDB, and all represent good candidates for further in-
vestigation of the OC survival in PDB.
A pathognomonic feature found in PDB patients is the
presence of inclusion bodies in OCs within affected bone;
because these inclusion bodies resemble the p62-aggregates
observed in diseases involving defective autophagy, dysreg-
ulation of the autophagy process may well be part of the
pathogenesis of PDB [49]. A dysregulation of the autophagy
process has been suggested in OCs from knock-in mice
expressing p62P394L [9], and an impaired autophagosomal
degradation of p62 has been observed in HEK 293 cell lines
transfected with PDB-related p62 variants [50]. OATL1/
TBC1D25, a Rab-GTPase-activating protein (Rab-GAP), of
which two spliced isoforms exist, is a newly-discovered
binding partner of Atg8/LC3, and has been shown to be
involved in a late stage of autophagosome maturation in
MEFs and COS-7 cells [51]. Our results have identifiedTBC1D25 as a potential candidate that may be worth inves-
tigating in PDB.
A limitation of our study is that expression of the identi-
fied genes and their RNA isoforms occurred in cells that
were analyzed in long-term in-vitro cultures. These condi-
tions may have been subject to stress-induced aberrant
gene expression, such as cancer susceptibility CASC4, or
genes related to p53 which is induced by DNA damage or
stress stimuli such as PIDD, and USP4. Yet, the proteins
encoded by these genes were found to be expressed in hu-
man OCs, and their splicing profiles were significantly
modified in OCs from PBD patients compared to controls.
In addition, except for the PIDD isoforms, the functional
impact of the different splice variants of the six genes re-
ported here remain elusive.
Conclusion
Our screening strategy led to the identification of AS
events that were significantly associated with pagetic
OCs, and our findings allowed the identification of
hitherto unknown players in OC biology. Further stud-
ies are warranted to identify the exact function of the
LGALS8, RHOT1, CASC4, USP4, TBC1D25, and PIDD
genes in human OCs, to investigate the regulation and
functional impact of the identified specific isoforms in OCs
using isoform-specific inhibitors, and their respective
contribution to the OC phenotype in PDB. Our results
may identify future avenues for research, as AS modu-
lation and its transposition to OC biology represent a
new area of research with wide-ranging potential inter-
est for explaining how these cells are regulated. This
new approach may also generate new concepts in the
pathogenesis of Paget’s disease.
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